Ranibizumab Combined With Verteporfin Photodynamic Therapy in Neovascular Age-related Macular Degeneration (FOCUS): Year 2 Results

Antoszyk, Andrew N.; Tuomi, Lisa; Chung, Carol; Singh, Angele

doi:10.1016/j.ajo.2007.12.029

Cited by 183 publications

(137 citation statements)

References 11 publications

Supporting

Mentioning

123

Contrasting

Unclassified

Order By: Relevance

“…About 34 % to 41 % of the patients treated with ranibizumab had gained more than 15 letters and, on average, VA was improved from baseline by 8.1 to 10.7 letters. Similar results were obtained in the FOCUS trial with 162 patients 16 . Some clinical trials that compared bevacizumab with ranibizumab showed that the two drugs have similar efficacy if applied in similar way [6][7][8] .…”

Section: Discussionsupporting

confidence: 75%

See 1 more Smart Citation

Risk for Low Visual Acuity After 1 and 2 Years of Treatment With Ranibizumab or Bevacizumab for Patients With Neovascular Age-Related Macular Degeneration

Westborg

Albrecht

Rosso

2017

Retina

View full text Add to dashboard Cite

Purpose: To investigate how patients with neovascular age-related macular degeneration treated with ranibizumab or bevacizumab respond to treatment in daily clinical practice. Methods: Data from the Swedish Macula Register on the treatment received by 3,912 patients during 2011 to 2014 is reported. Patients' characteristics at the first visit, visual acuity, number of injections, and reason for terminating the treatment if applicable are discussed. Furthermore, the risk of having poor vision (visual acuity under 60 Early Treatment Diabetes Retinopathy Study letters or approximately 20/60 Snellen) is calculated for the treated eye after 1 year and 2 years. Results: The treatment outcome depends on the visual acuity at the first visit. For patients with visual acuity more than 60 letters, the risk of having a visual acuity lower than 60 letters after 1 year or 2 years of treatment is approximately 20%. However, for patients with low visual acuity at diagnosis (fewer than 60 letters), the risk is approximately 60%. The risk of having a visual acuity lower than 60 letters does not depend on the choice of treatment drug. Conclusion: Treatment with anti-vascular endothelial growth factor intravitreal injections mainly maintains the visual acuity level, and only approximately 20% and 40% of the patients required vision rehabilitation after 1 year and 2 years, respectively.

show abstract

Section: Discussionsupporting

confidence: 75%

“…The efficacy of ranibizumab for the treatment of neovascular AMD was shown in several clinical trials 2,3,9,12,16,17 . The MARINA clinical trial compared ranibizumab against placebo in 716 patients 3 .…”

Section: Discussionmentioning

confidence: 99%

Risk for Low Visual Acuity After 1 and 2 Years of Treatment With Ranibizumab or Bevacizumab for Patients With Neovascular Age-Related Macular Degeneration

Westborg

Albrecht

Rosso

2017

Retina

View full text Add to dashboard Cite

show abstract

“…There is significant evidence demonstrating the efficacy of intravitreal ranibizumab in either improving or stabilising visual acuity in patients treated for CNV secondary to AMD. [24][25][26][27] Previous studies have demonstrated that ranibizumab has a prolonged effect in either stabilising or improving vision in CNV secondary to AS. 13 19 Vadalà et al 20 reported a series of nine patients who received 0.3 mg ranibizumab injections with a mean follow-up of 14 months.…”

Section: Discussionmentioning

confidence: 99%

Intravitreal ranibizumab for the treatment of choroidal neovascularisation secondary to angioid streaks

Shah

Amoaku

2012

Eye

View full text Add to dashboard Cite

Aims To assess the medium to long-term efficacy and safety of intravitreal ranibizumab for the treatment of choroidal neovascularisation (CNV) secondary to angioid streaks (AS). Methods A total of 12 eyes of nine patients treated with intravitreal ranibizumab (0.5 mg in 0.05 ml) for CNV secondary to AS were retrospectively identified. Efficacy of treatment was determined by changes in best-corrected LogMAR visual acuity (BCVA) and optical coherence tomography. Changes with respect to baseline BCVA were defined as improved or reduced with a gain or loss of more than 10 letters, respectively, or stable if remaining within 10 letters. Results Over a mean follow-up of 21.75 months (range: 1-54), patients received mean 5.75 (range: 2-15) intravitreal ranibizumab injections per affected eye. BCVA improved in three eyes (25%), stabilised in eight eyes (66.67%), and deteriorated in one eye (8.33%). There was no significant change in central retinal thickness (CRT) over the follow-up period (P ¼ 0.1072). No drug-related systemic side effects were recorded. Conclusion The long-term treatment of CNV secondary to AS with intravitreal ranibizumab showed a stabilisation in CRT and an improvement or stabilisation of BCVA. The absence of systemic side effects was reassuring. Further long-term prospective studies are required to validate these findings.

show abstract

“…[14][15][16] Use of an antiangiogenic factor can counteract the PDT-induced overexpression of VEGF and reduce its adverse effects. Two-year outcomes of FOCUS (RhuFab V2 ocular treatment combining the use of visudyne to evaluate safety) study showed that PDT combined with intravitreal ranibizumab was more effective than PDT alone in patients with predominantly classic CNV secondary to AMD, and that ranibizumab treatment reduced the need for re-treatment with PDT.…”

Section: Discussionmentioning

confidence: 99%

Randomised clinical trial of intravitreal Avastin vs photodynamic therapy and intravitreal triamcinolone: long-term results

Sacu

Michels

Prager

et al. 2009

Eye

View full text Add to dashboard Cite

Purpose To compare 1-year functional and anatomic outcomes of intravitreal bevacizumab (IVB) and photodynamic therapy plus intravitreal triamcinolone (PDT þ IVTA) combination in patients with neovascular age-related macular degeneration (AMD). Methods In this prospective, randomised, controlled clinical trial, 28 patients were included. All patients were randomised 1 : 1 to 0.04 ml/1 mg of IVB or PDT plus same day 0.1 ml/4 mg IVTA (PDT þ IVTA). Follow-up examinations were performed in monthly intervals in IVB group and every 3 months in PDT þ IVTA group. Main outcomes were change in mean visual acuity (VA), mean central retinal thickness (CRT) and the mean number of treatments. Results At month 12, mean VA improved to a 1.5-line gain in IVB group, and lost three letters in PDT þ IVTA group (P ¼ 0.02). Mean CRT was reduced from 357 lm at baseline to 244 lm at month 12 in IVB group and from 326 lm to 254 lm, respectively, in PDT þ IVTA group (P ¼ 0.8). The mean number of treatments was 6.8 in the IVB group vs 1.9 in the PDT þ IVTA group. No significant local or systemic safety concerns were detected during follow-up time. Conclusions Patients treated with IVB showed a significant better VA outcome compared with the PDT þ IVTA group despite the fact that both modalities showed equal potency in reducing CRT during a 12-month period.

show abstract

Ranibizumab Combined With Verteporfin Photodynamic Therapy in Neovascular Age-related Macular Degeneration (FOCUS): Year 2 Results

Cited by 183 publications

References 11 publications

Risk for Low Visual Acuity After 1 and 2 Years of Treatment With Ranibizumab or Bevacizumab for Patients With Neovascular Age-Related Macular Degeneration

Risk for Low Visual Acuity After 1 and 2 Years of Treatment With Ranibizumab or Bevacizumab for Patients With Neovascular Age-Related Macular Degeneration

Intravitreal ranibizumab for the treatment of choroidal neovascularisation secondary to angioid streaks

Randomised clinical trial of intravitreal Avastin vs photodynamic therapy and intravitreal triamcinolone: long-term results

Contact Info

Product

Resources

About